# AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.

> **NCT06137144** · PHASE1,PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 161 (estimated)

## Conditions studied

- Lymphoma
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma
- Peripheral T-cell Lymphoma (PTCL)
- PTCL-NOS
- ALCL
- AITL

## Interventions

- **DRUG:** AZD3470
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06137144
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-01-23
- **Primary completion:** 2029-04-30
- **Final completion:** 2029-04-30
- **Target enrollment:** 161 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06137144

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06137144, "AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06137144. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*